TY - JOUR
T1 - A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide
AU - Weir, Matthew R.
AU - Hsueh, Willa A.
AU - Nesbitt, Shawna D.
AU - Littlejohn, Thomas J.
AU - Graff, Alan
AU - Shojaee, Ali
AU - Waverczak, William F.
AU - Qian, Chunlin
AU - Jones, Christopher J.
AU - Neutel, Joel M.
PY - 2011/6
Y1 - 2011/6
N2 - In the prospective, open-label, titrate-to-goal Blood Pressure Control in All Subgroups With Hypertension (BP-CRUSH) study, 999 patients with hypertension uncontrolled on monotherapy (mean age, 55.6±11.4years; baseline blood pressure [BP], 153.7±9.2/91.9±8.6mm Hg) were switched to fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20mg. Patients were uptitrated every 4weeks to AML/OM 5/40 mg and 10/40mg to achieve BP <120/70mm Hg. Patients were subsequently uptitrated every 4weeks to AML/OM+hydrochlorothiazide (HCTZ) 10/40+12.5 mg and 10/40+25mg to achieve BP <125/75mm Hg. The primary end point, the cumulative percentage of patients achieving seated systolic BP <140mm Hg (<130mm Hg for patients with diabetes) by week 12, was 75.8%. The mean (±standard error) BP changes from baseline during the titration periods ranged from -14.2±0.4 mm Hg/-7.7±0.3mm Hg for AML/OM 5/20mg to -25.1±0.7 mm Hg/-13.7±0.4mm Hg for AML/OM+HCTZ 10/40+25mg. By week 20, the cumulative BP threshold of <140/90mm Hg was achieved by 90.3% of patients. An ambulatory BP monitoring substudy (n=243) showed that 24-hour efficacy was maintained. Treatment-emergent adverse events (TEAEs), mostly mild to moderate in severity, occurred in 529 patients (53.0%). Drug-related TEAEs occurred in 255 patients (25.5%). This well-tolerated, treat-to-goal algorithm enabled a large proportion of patients with uncontrolled hypertension on monotherapy to safely achieve BP control on single-pill AML/OM combination therapy or triple therapy with the addition of HCTZ.
AB - In the prospective, open-label, titrate-to-goal Blood Pressure Control in All Subgroups With Hypertension (BP-CRUSH) study, 999 patients with hypertension uncontrolled on monotherapy (mean age, 55.6±11.4years; baseline blood pressure [BP], 153.7±9.2/91.9±8.6mm Hg) were switched to fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20mg. Patients were uptitrated every 4weeks to AML/OM 5/40 mg and 10/40mg to achieve BP <120/70mm Hg. Patients were subsequently uptitrated every 4weeks to AML/OM+hydrochlorothiazide (HCTZ) 10/40+12.5 mg and 10/40+25mg to achieve BP <125/75mm Hg. The primary end point, the cumulative percentage of patients achieving seated systolic BP <140mm Hg (<130mm Hg for patients with diabetes) by week 12, was 75.8%. The mean (±standard error) BP changes from baseline during the titration periods ranged from -14.2±0.4 mm Hg/-7.7±0.3mm Hg for AML/OM 5/20mg to -25.1±0.7 mm Hg/-13.7±0.4mm Hg for AML/OM+HCTZ 10/40+25mg. By week 20, the cumulative BP threshold of <140/90mm Hg was achieved by 90.3% of patients. An ambulatory BP monitoring substudy (n=243) showed that 24-hour efficacy was maintained. Treatment-emergent adverse events (TEAEs), mostly mild to moderate in severity, occurred in 529 patients (53.0%). Drug-related TEAEs occurred in 255 patients (25.5%). This well-tolerated, treat-to-goal algorithm enabled a large proportion of patients with uncontrolled hypertension on monotherapy to safely achieve BP control on single-pill AML/OM combination therapy or triple therapy with the addition of HCTZ.
UR - http://www.scopus.com/inward/record.url?scp=79958282294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958282294&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7176.2011.00437.x
DO - 10.1111/j.1751-7176.2011.00437.x
M3 - Article
C2 - 21649839
AN - SCOPUS:79958282294
SN - 1524-6175
VL - 13
SP - 404
EP - 412
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 6
ER -